Pipeline

At Sage we're advancing a leading brain health portfolio.

Compound
Target Indications
Phase 1
Phase 2
Phase 3
Status
Postpartum Depression Commercial Products
ZURZUVAE®*
(zuranolone) CIV
  • Postpartum Depression
Marketed
Marketed
ZULRESSO®
(brexanolone) CIV injection
  • Postpartum Depression
Marketed
Marketed
Pipeline
Zuranolone*
(SAGE-217)
  • Major Depressive Disorder**
IN PHASE 3
IN PHASE 3
Dalzanemdor
(SAGE-718)
  • Huntington’s Disease Cognitive Impairment
IN PHASE 2
IN PHASE 2

  • Alzheimer’s Disease Mild Cognitive Impairment and Mild Dementia
IN PHASE 2
IN PHASE 2
Programs In Evaluation
  • SAGE-324***
    GABA Hypofunction
  • SAGE-689
    Acute GABA Hypofunction
  • SAGE-421
    NMDA Hypofunction
  • SAGE-319
    GABA Hypofunction